If you have a burning desire to respond to a paper published in ADC or FeN, why not make use of our “rapid response” option? Log on to our website (www.archdischild.com), find the paper that interests you, click on “full text” and send your response by email by clicking on “submit a response”. Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eLetters” on our homepage.

The editors will decide, as before, whether to also publish it in a future paper issue.

Oral clodronate as treatment of osteogenesis imperfecta

The benefits of treatment with intravenous pamidronate in osteogenesis imperfecta (OI) have recently been reported. These include reduced bone resorption, increased bone density, and improved clinical outcomes as judged by apparently lower fracture rates. We would like to report a single case of OI treated by the orally administered bisphosphonate, clodronate, with good effect.

A boy, whose mother was affected with clinically diagnosed type 1 osteogenesis imperfecta, was referred to our unit aged 13 1/2 with a recent onset of severe back pain that had required hospital admission. He appeared of normal stature with blue sclerae and was able to walk independently. He had sustained four previous limb fractures; lateral radiographs of the thoracic and lumbar spine confirmed three vertebral wedge fractures. He was 158.9 cm tall (10th centile) and weighed 49 kg (25th centile). Lumbar spine bone mineral density scanning by dual x ray absorpiometry (DXA, Hologic QDR-1000, Hologic, Bedford, MA) revealed a BMD of 0.396 g/cm^2 (Z score −5.22, comparing his value to the average young man). Fasting urinary hydroxyproline/creatinine ratio, an index of bone resorption, was 96.6.

With informed parental consent for “off label” usage, he was commenced on oral sodium clodronate (Bonefos, Leiras Oy, Turku, Finland) at a dose of 400 mg daily. Dietary intake of calcium and vitamin D was above the estimated average requirement and supplementation was not given. Subsequent BMD scanning after one year of therapy showed an improvement of bone density by 7.8% to 0.468 g/cm^2 with a consequent increase in the BMD Z score to −3.09.

Treatment with clodronate was continued for five years, during which time he did not sustain any new low trauma fractures. By the end of treatment, his BMD was 0.552 and his Z score had improved from −5.22 at first referral to −4.59. The fasting urinary hydroxyproline/creatinine ratio was decreased by 86% compared to baseline (13.6 v 96.6). Clodronate was discontinued for eight months; during this time his BMD remained stable but the Z score showed a small decline. His height at that stage lay on the 50th centile (176 cm) and his weight on the 10th (58 kg). The BMD remained considerably below the normal value and clodronate was recommenced at a dose of 800 mg daily.

Eight years after initial referral, his bone mineral density had increased by 60.6% to 0.613 g/cm^2 (Z score −4.16). To compensate for the expected increase in bone size, the bone mineral adjusted density (BMD) was computed (BMD_{L1–L4}/square root of area_{L1–L4}) and showed an improvement of 24.6% in BMD over the duration of therapy. Clodronate was discontinued when the patient was aged 22. He had reached a height of 177.4 cm and a weight of 60.8 kg, and the spine BMD Z score was −3.92. He had suffered no atraumatic fractures since commencing oral clodronate.

The rationale in using bisphosphonates for osteogenesis imperfecta is the inhibition of osteoclastic bone resorption leading to increased bone density and a potentially lower risk of fracture. This young man exhibited a good response to therapy with oral clodronate, suffering no adverse reactions. The increase in height of 18 cm over eight years, moving him from the 10th to 50th centile, suggests that his growth was not impaired by therapy. Many studies have shown that clodronate does not impair mineralisation. We are unable to determine the contribution of remodelling of vertebral fractures to his height gain.

A limitation of this report is that pubertal status was not documented at presentation. However, the increases in lumbar spine density are in excess of the expected average rates in growing children (3–6% per year and 14–16% during puberty). The increase was also observed following adjustment for bone growth by BMD and Z scores relating the measured BMD to age matched controls. The Z score (−5.22 to −3.92) improvement during therapy was not dissimilar to that reported with pamidronate in younger children.

We agree that there is increasing evidence of a role for bisphosphonate therapy as part of the multidisciplinary management of osteogenesis imperfecta. Oral clodronate in our patient appeared to elicit a similar response to that of cyclical intravenous pamidronate, suggesting that orally administered bisphosphonates may be of value in the management of this disease.

References


Serum prolactin in coeliac schoolchildren

Literature published suggests that in children with coeliac disease (CD) serum prolactin concentrations are increased, and correlate with the grade of mucosal atrophy. It has been proposed that prolactin is a possible marker of disease activity. Other studies, however, have failed to show this correlation in children with CD.

We studied prolactin levels in children with CD, and the correlation with the severity of intestinal mucosal atrophy.

We used samples from a serum bank obtained during a mass screening for CD in Sardinian schoolchildren, using both antiretdomyosial antibodies and antigliadin antibodies as screening tests, as previously described. The sample included 20 children with CD and 5.90 (2.6) ng/ml in controls (no statistically significant difference). No correlation was found between prolactin concentrations and the degree of intestinal damage (Marsh criteria).

Our study did not confirm the increased prolactin concentrations in children with CD reported by Reifen and colleagues. Our population differed somewhat in that there was a higher mean age (12.9 v 11.3 years), a narrower age range (11.5–14.4 years) and 40 sex and age matched normal children (32 girls, 8 boys, mean age 13.0 years, range 11.2–14.8 years). All subjects were euthyroid. Prolactin was assayed in duplicate using a commercial immunoradiometric method; results were analysed by analysis of covariance.

Data are expressed as mean (SE), Prolactin levels were 4.62 (2.1) ng/ml in patients with CD and 5.90 (2.6) ng/ml in controls (no statistically significant difference). No correlation was found between prolactin concentrations and the degree of intestinal damage (Marsh criteria).

Our study did not confirm the increased prolactin concentrations in children with CD reported by Reifen and colleagues. Our population differed somewhat in that there was a higher mean age (12.9 v 11.3 years), a narrower age range (11.5–14.4 v 5–18 years), and a different girl:boy ratio (4:1 v 1:1). Furthermore, our study included three potential coeliac subjects (with antiendomysium antibodies positivity but normal intestinal biopsy) and 11 asymptomatic coeliac children. The hypothesis that the normal prolactin values observed in our study may be due at least in part to the different clinical characteristics of the population studied is plausible, but its validation requires a specifically designed study.

R U Ashford, A Dey, K Kayan, E V McCloskey, J A Kanis
Sheffield Metabolic Bone Unit, Sheffield, UK
robert.ashford@virgin.net
Acknowledgement

Some preferential funding grant 34/39-2000 (Coeliac disease and iodine-deficiency diseases) to GD from Regione Sardegna.

G Fanciulli, P A Tomasi, G Delitala
Dipartimento-Struttura Clinica Medica-Patologia Speciale Medica, University of Sassari, Italy
A D’Appello, G Fanciulli Sr
Divisione di Pediatria, Ospedale Civile di Alghero.

Correspondence to: Dr G Fanciulli, Dipartimento-Struttura Clinica Medica-Patologia Speciale Medica, University of Sassari, Viale S Pietro 8, 07100 Sassari, Italy; gffanciulli@uniss.it

References


A Clinical Guide to Inherited Metabolic Diseases, 2nd edn

Edited by JTR Clarke UK: Cambridge University Press, 2002, £29.95, pp 306. ISBN 0521890764

Dr Clarke’s enthusiasm and erudition are evident on every page of this book, which is handily sized, and, wonder of wonders, costs only £30.

Most of the chapters are written with a clinical-based approach, and the chapters on basic principles in understanding inherited metabolic disease, neonatal screening, hypoglycaemia, metabolic acidosis, storage diseases, and dysmorphism will be read with a sensation of increasing revelation by just about any paediatrician, and those with a secure background in biochemistry and metabolic disease will pick up many nuggets of wisdom.

Why then, do I simply not recommend every paediatrician who sometimes deals with metabolic problems—and there must be few of us who do—not to rush out and buy a copy before such a gem either goes out of print or rises in price? My caveat is that this book’s basic principles in understanding inherited metabolic disease will pick up many nuggets of wisdom.

Most of the chapters are written with a clinical-based approach, and the chapters on basic principles in understanding inherited metabolic disease, neonatal screening, hypoglycaemia, metabolic acidosis, storage diseases, and dysmorphism will be read with a sensation of increasing revelation by just about any paediatrician, and those with a secure background in biochemistry and metabolic disease will pick up many nuggets of wisdom.

Why then, do I simply not recommend every paediatrician who sometimes deals with metabolic problems—and there must be few of us who do—not to rush out and buy a copy before such a gem either goes out of print or rises in price? My caveat is that this book’s basic principles in understanding inherited metabolic disease will pick up many nuggets of wisdom.

The final chapter talks about setting up a headache clinic, including a discussion on diagnostic tests. There is a headache questionnaire for parents, which I would find very helpful. There is also advice on the role of the multidisciplinary team in management.

This book would be a valuable addition to a general paediatric department, both in outpatient and for reference when on call.

A Morjaria

CORRECTIONS

In the article by Nixon et al (Arch Dis Child 2002;87:306–11); Dr Claire Wainwright should have been included as an author. Dr Wainwright’s contribution was the establishment of the methodology and early patient recruitment and testing. Dr Wainwright moved from The Royal Children’s Hospital at the end of 1997, and was funded by The Royal

Childhood Headache


Headaches in children are a common problem—70% of school children have headaches at least once a year, with 25% suffering from recurrent headaches. This book is part of the Clinics in Developmental Medicine series, and provides a comprehensive overview of the subject. The book is divided into clear chapters, which makes it easy to dip into. It includes interesting sections on pain percep-

www.archdischild.com

Arch Dis Child: first published as 10.1136/adc.88.10.945-a on 19 September 2003. Downloaded from

http://adc.bmj.com/ on May 11, 2022 by guest. Protected by copyright.
Children's Hospital Foundation, Brisbane and the Cystic Fibrosis Research Inc, Queensland. The authors apologise for the omission.

The authors of the letter “Childhood SARS in Singapore” in the August issue (Arch Dis Child 2003;88:742) were written incorrectly. The authors names should be P Van Bever, C P P Hia, S C Quek.

In the acknowledgements for the leading article by Duke et al (Arch Dis Child 2003;88:563–5), Dr Diana Silimperi should have been acknowledged as part of the Paediatric Quality Care Group. The authors apologise for the error.

An error occurred in the paper by Riordan M, Rylance G, Berry K in the November issue. (Poisoning in children 1: General management. Arch Dis Child 2002;87:393–6). In Table 2, pupillary constriction associated with signs of increased sympathetic nervous system activity should read as mild pupillary dilation. Anticholinergic agents are likely to produce a more marked dilation. The authors apologise for the error.